Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse J Salk

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Environmental and Molecular Mutagenesis|October 10, 2019
Next-Generation Genotoxicology: Using Modern Sequencing Technologies to Assess Somatic Mutagenesis and Cancer RiskJesse J Salk, Scott R Kennedy
Seminars in Cancer Biology|October 19, 2010
Passenger mutations as a marker of clonal cell lineages in emerging neoplasiaJesse J Salk, Marshall S Horwitz
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Optimization of DNA polymerase mutation rates during bacterial evolutionErn Loh, Jesse J Salk, Lawrence A Loeb
Cancer Research|June 11, 2009
Cancer genome sequencing--an interim analysisEdward J Fox, Jesse J Salk, Lawrence A Loeb
Annual Review of Pathology|September 12, 2009
Mutational heterogeneity in human cancers: origin and consequencesJesse J Salk, Edward J Fox, Lawrence A Loeb
Nature Reviews. Genetics|March 27, 2018
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutationsJesse J Salk, Michael W Schmitt, Lawrence A Loeb
Aging Cell|June 5, 2014
Response to: 'when man got his mtDNA deletions?'Sean D Taylor, Jesse J Salk, Jason H Bielas
Genome Medicine|March 19, 2016
Exploring the implications of distinct mutational signatures and mutation rates in aging and cancerEdward J Fox, Jesse J Salk, Lawrence A Loeb
Nature Reviews. Clinical Oncology|October 21, 2015
The influence of subclonal resistance mutations on targeted cancer therapyMichael W Schmitt, Lawrence A Loeb, Jesse J Salk
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Risks of double-counting in deep sequencingMichael W Schmitt, Edward J Fox, Jesse J Salk
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Environmental and Molecular Mutagenesis|October 10, 2019
Next-Generation Genotoxicology: Using Modern Sequencing Technologies to Assess Somatic Mutagenesis and Cancer RiskJesse J Salk, Scott R Kennedy
Seminars in Cancer Biology|October 19, 2010
Passenger mutations as a marker of clonal cell lineages in emerging neoplasiaJesse J Salk, Marshall S Horwitz
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Optimization of DNA polymerase mutation rates during bacterial evolutionErn Loh, Jesse J Salk, Lawrence A Loeb
Cancer Research|June 11, 2009
Cancer genome sequencing--an interim analysisEdward J Fox, Jesse J Salk, Lawrence A Loeb
Annual Review of Pathology|September 12, 2009
Mutational heterogeneity in human cancers: origin and consequencesJesse J Salk, Edward J Fox, Lawrence A Loeb
Nature Reviews. Genetics|March 27, 2018
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutationsJesse J Salk, Michael W Schmitt, Lawrence A Loeb
Aging Cell|June 5, 2014
Response to: 'when man got his mtDNA deletions?'Sean D Taylor, Jesse J Salk, Jason H Bielas
Genome Medicine|March 19, 2016
Exploring the implications of distinct mutational signatures and mutation rates in aging and cancerEdward J Fox, Jesse J Salk, Lawrence A Loeb
Nature Reviews. Clinical Oncology|October 21, 2015
The influence of subclonal resistance mutations on targeted cancer therapyMichael W Schmitt, Lawrence A Loeb, Jesse J Salk
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Risks of double-counting in deep sequencingMichael W Schmitt, Edward J Fox, Jesse J Salk
Pageof 5